Beranda › Kanker Paru › North Carolina › Durham
Uji klinis Kanker Paru di Durham, NC
32 studi untuk Kanker Paru mencari peserta di lokasi sekitar Durham (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
The Vanguard Study: Testing a New Way to Screen for Cancer
Menerima pesertaSukarelawan sehat diterima
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- Duke University Medical Center, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- Duke University, Durham
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Durham VA Medical Center, Durham
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Menerima pesertaFase 3
- Durham VA Medical Center, Durham
- Duke University Medical Center, Durham
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Menerima pesertaFase 3
- Duke Cancer Center, Durham
A Study of PHN-012 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1
- PHN-012-001 Site, Durham
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Menerima pesertaFase 3
- UNC Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi jauhnya
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Menerima pesertaFase 3
- Duke University Medical Center, Durham
Study of Trilaciclib and Lurbinectidin
Menerima pesertaFase 2
- Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill · 10 mi jauhnya
Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
Menerima pesertaFase 2
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill · 10 mi jauhnya
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Menerima pesertaFase 1/2
- Duke University School of Medicine, Durham
Effects of Infusion Timing on Treatment Response in Solid Tumors
Menerima pesertaFase 2
- University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill · 10 mi jauhnya
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Menerima pesertaFase 3
- Duke Cancer Institute, Durham
- University of North Carolina Medical Center, Chapel Hill · 10 mi jauhnya
Health Education Approach to Lung Screening
Menerima pesertaSukarelawan sehat diterima
- University of North Carolina-Chapel Hill, Carrboro · 11 mi jauhnya
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Menerima pesertaFase 1
- Xencor Investigative Site, Durham
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Menerima pesertaFase 1/2
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi jauhnya
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Menerima peserta
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · 10 mi jauhnya
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Menerima pesertaFase 2
- University of North Carolina, Chapel Hill · 10 mi jauhnya
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Menerima pesertaFase 1
- Research Site, Durham
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Durham VA Medical Center, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Menerima pesertaFase 1
- Duke Cancer Center, Durham
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Menerima pesertaFase 1/2
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi jauhnya
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- Durham VA Medical Center, Durham
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
Menerima pesertaSukarelawan sehat diterima
- Duke University, Durham
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Menerima peserta
- Durham VA Medical Center, Durham, NC, Durham
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Menerima pesertaFase 1
- Duke Cancer Institute, Durham
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
Menerima pesertaFase awal 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi jauhnya
UNC Pleural Fluid Registry
Menerima pesertaStudi observasional
- UNC Lingeberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Menerima pesertaFase 2
- University of North Carolina, Chapel Hill · 10 mi jauhnya
Uji klinis Kanker Paru di kota lain
- Houston, TX78 studi
- Boston, MA62 studi
- New York City, NY60 studi
- Los Angeles, CA45 studi
- Arlington, VA41 studi
- Washington, DC41 studi
- Chicago, IL41 studi
- Baltimore, MD40 studi
- Nashville, TN40 studi
- St. Louis, MO39 studi
- Columbus, OH37 studi
- Philadelphia, PA36 studi
Studi lain di Durham
- Kanker Payudara64 studi
- Kanker (semua jenis)58 studi
- Kanker Paru Non-Sel Kecil39 studi
- Mieloma Multipel37 studi
- Leukemia Mieloid Akut33 studi
- Kanker Metastatik33 studi
- Kanker Prostat32 studi
- Kanker Kolorektal28 studi
- Kanker Ovarium27 studi
- Leukemia Limfositik Kronis27 studi
- Gagal Jantung26 studi
- Kanker Pankreas24 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.